Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-sclerostin mAb biosimilar
- Development stage
- Preclinical
- Lead developer
- Saya Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Anti-sclerostin mAb biosimilar is a monoclonal antibody biosimilar candidate under development by Saya Bio. It is designed to target and inhibit sclerostin, a glycoprotein secreted by osteocytes that acts as a negative regulator of bone formation by inhibiting the Wnt/β-catenin signaling pathway. By blocking sclerostin, the antibody promotes osteoblast activity and bone formation while also reducing bone resorption. The candidate is currently in the cell line development stage (preclinical) for the treatment of bone health disorders, such as osteoporosis, and is a biosimilar of romosozumab.
- Other names
- romosozumab biosimilar
02
Targets
LRP5 (Low-density lipoprotein receptor-related protein 5)LRP6 (Low-density lipoprotein receptor-related protein 6)SOST (Sclerostin)
Beyond the preview
Go deeper on Anti-sclerostin mAb biosimilar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-sclerostin mAb biosimilar.